Astellas asks women 'What's VMS' in its latest TV ad.
What causes hot flashes? Astellas ramps up educational campaign ahead of FDA decision
Astellas’ fezolinetant isn’t due for an FDA decision until February in vasomotor symptoms (VMS) associated with menopause — but the pharma company isn’t waiting until then …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
